NEXT-GENERATION NK CELL-BASED IMMUNOTHERAPIES FOR HARD-TO-TREAT CANCERS
Associate Professor Fernando S. F. Guimaraes, PhD, GAICD
Group Leader, Translational Innate Immunotherapy
Frazer Institute, Faculty of Medicine,
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | February 2025
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
A/Prof Guimaraes completed his PhD at the Institut Pasteur and pursued postdoctoral research at QIMR Berghofer and WEHI before joining UQ in 2019. His pioneering work has significantly advanced understanding of immune evasion mechanisms in cancer, leading to potential breakthroughs in NK cell therapies. His research integrates systems biology, experimental oncology, and bioinformatics to design novel, targeted treatments resistant to tumour-induced immunosuppression. His contributions have earned him numerous awards, including the QLD Tall Poppy, UQ Frazer Institute Rising Star, Translational Research Institute – Connecting with the Clinic Awards.
He has published extensively in top-tier journals, secured and led major research funding (NHMRC, MRFF, US DoD) focused on NK cell therapies. A/Prof Guimaraes also plays a key role in mentoring early-career researchers, serving as the Chair of the Research Committee at Cure Cancer Australia and leading multiple international collaborations.
Source: supplied
https://orcid.org/0000-0002-2037-8946
-
Ocular disease and early onset myopia
Dr Mountford has successfully established Western Australia’s first and only ocular genetic screening platform using zebrafish and utilises this model to help elucidate some of the complex gene-environment interactions responsible for the development of myopia.
-
Peripheral intravenous catheter management
Dr Grace Xu is a clinician-researcher, senior nurse practitioner, and emerging implementation scientist with more than 16 years of emergency nursing experience. She is a Fellow of the College of Emergency Nurses Australasia and a Centaur Fellow. She also leads the Early Career Researcher/Clinician Researcher portfolio within the Alliance for Vascular Access Teaching and Research group.
-
Metabolic phenotyping, lipidomics & bioinformatics in dementia
Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.
His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.
